Pasar al contenido principal

ESTRATEGIAS QUIMIO-INMUNOTERAPEUTICAS OPTIMIZADAS EN NANOPARTICULAS PARA EL TRATAMIENTO DE LAS LEISHMANIOSIS CUTANEAS

PID2023-148406OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD COMPLUTENSE DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Fluidity as a key determinant of stability in PEGylated lipid nanoparticles loaded with a TLR7 agonist

  • Palomino-Cano, Carmen
  • Mera-Delgado, M.Carmen
  • Pons, Ramon
  • Moreno, Esther
  • Larrea, Esther
  • Aguirre, Lecnia
  • Mamani, Elisa
  • Martínez-Ohárriz, M.Cristina
  • Irache, Juan M.
  • Carrión Herrero, Francisco Javier
  • Espuelas, Socorro
TLR7 agonists are low molecular weight immunomodulators that can rapidly diffuse from the site of administration, often leading to undesired systemic inflammatory effects. To mitigate toxicity and broaden therapeutic applicability, imiquimod (IMQ), a widely used TLR7 agonist, was encapsulated in lipid-based nanocarriers (LNCs). A fractional factorial design (24−1) was employed to examine the influence of formulation variables—liquid lipid (LL), solid lipid (SL), lipid molar ratio, and surfactant—on particle size, encapsulation efficiency, colloidal stability, and cytotoxicity in bone marrow-derived macrophages (BMDMs) and erythrocytes. Screening indicated that LL type and SL/LL ratio were the most critical factors affecting both physicochemical and biological properties. Based on these insights, a refined study focused on C10–C18 triglycerides as SL and PEG40-stearate as surfactant, while varying LL (oleic acid or isostearic acid) at two SL/LL molar ratios (2.5:1 and 1:2.5). Structural and biophysical analyses (DSC, SAXS, DPH and Laurdan fluorescence) showed that lipid shell fluidity dictated PEG conformation at the particle surface: rigid shells promoted a hydrated brush-like PEG layer, whereas fluid shells yielded a collapsed, less stable arrangement. The optimal formulation (triglycerides: oleic acid, 2.5:1) generated nanoparticles of 45 nm with efficient IMQ encapsulation and low cytotoxicity. This system effectively reprogrammed BMDMs toward a pro-inflammatory (M1) phenotype, confirmed by gene and cytokine expression. Altogether, these results highlight the importance of formulation design and nanostructural characterization in developing nanocarrier systems that enable safer and more versatile delivery of potent immunotherapeutics such as IMQ
Docta Complutense
Publicación Artículo científico (JournalArticle)

Gardiquimod Nanoemulsion Targets Cutaneous Leishmaniasis Lesions Reducing Systemic Toxicity and Parasite Burden

  • Palomino‐Cano, Carmen
  • Mera‐Delgado, M. Carmen
  • Moreno, Esther
  • Larrea, Esther
  • Aguirre, Lecnia
  • Zanatta, Jonathan Miguel
  • Barros‐Carvalho, Sónia
  • Duarte, Iola F.
  • Silvestre, Ricardo
  • Irache, Juan M.
  • Carrión Herrero, Francisco Javier
  • Espuelas, Socorro
Cutaneous leishmaniasis (CL) remains difficult to treat because Leishmania parasites persist within dermal macrophages and suppress their microbicidal activity, promoting chronic infection. Toll-like receptor (TLR) agonists can restore macrophage effector functions, but their therapeutic use is limited by systemic toxicity. Here, we developed a lipid-based nanoemulsion (NE) for the systemic delivery of the TLR7 agonist gardiquimod (GDQM) to improve macrophage targeting and reduce off-target inflammatory effects. Following intravenous administration, GDQM-NEs efficiently accumulated in dermal lesions and significantly reduced systemic cytokine release compared with free GDQM, resulting in an improved safety profile. Importantly, nanoencapsulation preserved GDQM antileishmanial activity achieving an approximately 2-log reduction in parasite burden. Treatment induced both Th1-associated cytokines (IFN-γ and IL-12p70) and regulatory responses, including IL-10 production and FoxP3+ regulatory T-cell expansion. Despite efficient lesion accumulation, CD86 upregulation was detected in macrophages from draining lymph nodes (dLNs) but not at the lesion site, indicating limited local macrophage activation. These findings indicate that GDQM-NEs effectively overcome major delivery and safety barriers associated with systemic TLR7 agonist administration, whereas the lesion microenvironment and TLR-driven regulatory mechanisms remain key constraints on therapeutic efficacy. Combining TLR agonists with strategies that counteract these local suppressive pathways may further enhance treatment outcomes in CL
Dadun. Depósito Académico Digital de la Universidad de Navarra
Publicación Artículo científico (JournalArticle)

Fluidity as a key determinant of stability in PEGylated lipid nanoparticles loaded with a TLR7 agonist

  • Mera-Delgado, M.C. (María del Carmen)|||/items/9af55ddd-7b04-48b0-a707-9ba255d2c552
  • Palomino-Cano, C. (Carmen)|||/items/65bd9063-648f-4c5f-86ef-7911ea38aa57
  • Pons, R. (Ramon)|||/items/a2fd2f16-f6fa-4f00-80b8-fdacebef3e78
  • Moreno, E. (Esther)|||/items/e9c6c350-8b74-4554-86fd-4a8a7ff563a4
  • Larrea-Leoz, E. (Esther)|||/items/37a0521f-3293-4001-85d1-bc71241d8a83
  • Aguirre-Urrutia, L. (Lecnia)|||/items/1ba2d77a-ceb8-4ade-8302-cac2145381d1
  • Martínez-Oharriz, M.C. (María Cristina)|||/items/05dc7a92-e9c7-4839-8f0b-fb5104a3e43e
  • Irache-Garreta, J.M. (Juan Manuel)|||/items/c7cbbe9e-faeb-47e1-b7e8-2d956ca50173
  • Carrión, J. (Javier)|||/items/c5f11c05-d324-4ab4-9598-89b0163ce565
  • Espuelas, S. (Socorro)|||/items/b57c05de-0bc4-4fcf-ae1e-c9b2fb92964c
  • Mamani, E. (Elisa)|||/items/af75330b-f27f-43c4-a6df-30408e54b793
TLR7 agonists are low molecular weight immunomodulators that can rapidly diffuse from the site of administration, often leading to undesired systemic inflammatory effects. To mitigate toxicity and broaden therapeutic applicability, imiquimod (IMQ), a widely used TLR7 agonist, was encapsulated in lipid-based nanocarriers (LNCs). A fractional factorial design (24− 1) was employed to examine the influence of formulation variables—liquid lipid (LL), solid lipid (SL), lipid molar ratio, and surfactant—on particle size, encapsulation efficiency, colloidal stability, and cytotoxicity in bone marrow-derived macrophages (BMDMs) and erythrocytes. Screening indicated that LL type and SL/LL ratio were the most critical factors affecting both physicochemical and biological properties. Based on these insights, a refined study focused on C10–C18 triglycerides as SL and PEG40-stearate as surfactant, while varying LL (oleic acid or isostearic acid) at two SL/LL molar ratios (2.5:1 and 1:2.5). Structural and biophysical analyses (DSC, SAXS, DPH and Laurdan fluorescence) showed that lipid shell fluidity dictated PEG conformation at the particle surface: rigid shells promoted a hydrated brush-like PEG layer, whereas fluid shells yielded a collapsed, less stable arrangement. The optimal formulation (triglycerides: oleic acid, 2.5:1) generated nanoparticles of 45 nm with efficient IMQ encapsulation and low cytotoxicity. This system effectively reprogrammed BMDMs toward a pro-inflammatory (M1) phenotype, confirmed by gene and cytokine expression. Altogether, these results highlight the importance of formulation design and nanostructural characterization in developing nanocarrier systems that enable safer and more versatile delivery of potent immunotherapeutics such as IMQ.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Antiprotozoal Potential of Cultivated Geranium macrorrhizum Against Giardia duodenalis, Trichomonas gallinae and Leishmania infantum

  • Marcos-Herraiz, Sara
  • Irisarri-Gutiérrez, María José
  • Carrión, Javier
  • Azami-Conesa, Iris
  • Suárez Lombao, Rodrigo
  • Navarro-Rocha, Juliana
  • Quilez del Moral, José Francisco
  • Fernández Barrero, Alejandro
  • Ochoa Larrigan, Eneko
  • González-Coloma, Azucena
  • Gómez-Muñoz, María Teresa
  • Bailén, María
This article belongs to the Section Molecular Pharmacology., Plant-derived natural products are an invaluable source of structurally diverse secondary metabolites with ecological and pharmacological significance. Geranium macrorrhizum, a species known for producing essential oils rich in monoterpenoids and sesquiterpenes, has been scarcely explored for its antiparasitic potential. This study represents the first comprehensive evaluation of the antiprotozoal activity of G. macrorrhizum obtained from cultivated plants. Plant material was produced under controlled greenhouse cultivation systems, ensuring high-quality and reproducible metabolite profiles. Essential oils were obtained through hydrodistillation and chemically characterized by Gas Chromatography-Mass Spectrometry (GC–MS). In vitro assays were conducted against Giardia duodenalis, Trichomonas gallinae, and Leishmania infantum to assess antiparasitic efficacy and cytotoxicity. The results demonstrated strong activity of essential oils against Trichomonas gallinae, and Leishmania infantum, indicating the relevance of lipophilic compounds—especially germacrone—as key bioactive constituents. Germacrone exhibited strong and selective antiparasitic activity, outperforming its structural analogues. Microscopic analyses revealed distinct parasite-specific morphological alterations, differing from those induced by conventional drugs such as metronidazole and amphotericin B. These findings highlight G. macrorrhizum obtained through biotechnological cultivation as a novel and sustainable source of natural antiprotozoal agents. The study underscores the importance of integrating controlled cultivation with phytochemical and biological evaluation to advance the discovery of innovative bioactive compounds., This work has been partially financed by Grants PID2020-114207RB-I00 (Spanish Ministry of Science and Innovation), PID2019-106222RB-C32/SRA (State Research Agency), PID2023-148406OB-I00 (Spanish Ministry of Science and Innovation and Universities), PID2024-156361OB-C22 (Spanish Ministry of Science and Innovation and Universities)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Kinetoplast-Directed Therapies: A Selective Mitochondrial Approach to Combat Leishmaniasis

  • Botero-Buitrago, Jenny A.
  • Cardozo-Muñoz, Juan Camilo
  • Cisneros, David
  • Santamaría-Aguirre, Javier
  • Torres, Koraima
  • Espuelas, Socorro
  • Carrión, Javier
  • Dardonville, Christophe
This article belongs to the Collection Drug Discovery and Development for Tropical Diseases (TDs), The leishmaniases are a group of neglected tropical diseases caused by kinetoplastid protozoa of the genus Leishmania, transmitted by phlebotomine sandflies. In the absence of a human vaccine, current chemotherapeutic options remain suboptimal due to limited target selectivity, high cost, restricted availability in endemic low-resource regions, and escalating parasite resistance. This review highlights recent advances in rational drug design directed at the kinetoplast—a distinctive mitochondrial organelle critical for parasite viability. Different targets (e.g., kDNA, G-quadruplex, topoisomerases) and innovative approaches employing mitochondrion-targeted small molecules are discussed, as well as ligand-functionalized nanoparticle delivery systems that can transport bioactive agents to the parasite’s mitochondrial microenvironment. These strategies highlight the kinetoplast’s strong translational relevance as a selective antileishmanial target. By exploiting its unique molecular machinery, these strategies may offer improved parasite selectivity, although potential mitochondrial liabilities in host cells must be carefully evaluated., Funding by Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033) (Co-funded by European Regional Development Fund. ERDF, “A way to build Europe”, by the “European Union”), through the grants PID2020-114207RB-I00, PID2022-136438OB-I00 and PID2023-148406OB-I00, is gratefully acknowledged. JCM is supported by a PhD scholarship (PREP2022-000704) funded by Ministerio de Ciencia e Innovación (MCIN/AEI/10.13039/501100011033). David Cisneros is supported by a PhD scholarship (PIPF-2022SAL-GL-24344) from Comunidad de Madrid, Spain., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Antiprotozoal Potential of Cultivated Geranium macrorrhizum Against Giardia duodenalis, Trichomonas gallinae and Leishmania infantum

  • Marcos-Herraiz, Sara
  • Irisarri-Gutiérrez, María José
  • Carrión, Javier
  • Azami Conesa, Iris
  • Suárez Lombao, Rodrigo
  • Navarro-Rocha, Juliana
  • Quilez del Moral, José Francisco
  • Fernández Barrero, Alejandro
  • Ochoa Larrigan, Eneko
  • González-Coloma, Azucena
  • Gómez-Muñoz, María Teresa
  • Bailén, María
Plant-derived natural products are an invaluable source of structurally diverse secondary metabolites with ecological and pharmacological significance. Geranium macrorrhizum, a species known for producing essential oils rich in monoterpenoids and sesquiterpenes, has been scarcely explored for its antiparasitic potential. This study represents the first comprehensive evaluation of the antiprotozoal activity of G. macrorrhizum obtained from cultivated plants. Plant material was produced under controlled greenhouse cultivation systems, ensuring high-quality and reproducible metabolite profiles. Essential oils were obtained through hydrodistillation and chemically characterized by Gas Chromatography-Mass Spectrometry (GC–MS). In vitro assays were conducted against Giardia duodenalis, Trichomonas gallinae, and Leishmania infantum to assess antiparasitic efficacy and cytotoxicity. The results demonstrated strong activity of essential oils against Trichomonas gallinae, and Leishmania infantum, indicating the relevance of lipophilic compounds—especially germacrone—as key bioactive constituents. Germacrone exhibited strong and selective antiparasitic activity, outperforming its structural analogues. Microscopic analyses revealed distinct parasite-specific morphological alterations, differing from those induced by conventional drugs such as metronidazole and amphotericin B. These findings highlight G. macrorrhizum obtained through biotechnological cultivation as a novel and sustainable source of natural antiprotozoal agents. The study underscores the importance of integrating controlled cultivation with phytochemical and biological evaluation to advance the discovery of innovative bioactive compounds.